Multiple Factors to Assist Human-derived Induced Pluripotent Stem Cells to Efficiently Differentiate into Midbrain Dopaminergic Neurons

Overview

Journal Neural Regen Res

Date 2023 Oct 16

PMID 37843228

Authors

Yalan Chen

Junxin Kuang

Yimei Niu

Hongyao Zhu

Xiaoxia Chen

Kwok-Fai So

Anding Xu

Lingling Shi

Affiliations

Soon will be listed here.

Abstract

Midbrain dopaminergic neurons play an important role in the etiology of neurodevelopmental and neurodegenerative diseases. They also represent a potential source of transplanted cells for therapeutic applications. In vitro differentiation of functional midbrain dopaminergic neurons provides an accessible platform to study midbrain neuronal dysfunction and can be used to examine obstacles to dopaminergic neuronal development. Emerging evidence and impressive advances in human induced pluripotent stem cells, with tuned neural induction and differentiation protocols, makes the production of induced pluripotent stem cell-derived dopaminergic neurons feasible. Using SB431542 and dorsomorphin dual inhibitor in an induced pluripotent stem cell-derived neural induction protocol, we obtained multiple subtypes of neurons, including 20% tyrosine hydroxylase-positive dopaminergic neurons. To obtain more dopaminergic neurons, we next added sonic hedgehog (SHH) and fibroblast growth factor 8 (FGF8) on day 8 of induction. This increased the proportion of dopaminergic neurons, up to 75% tyrosine hydroxylase-positive neurons, with 15% tyrosine hydroxylase and forkhead box protein A2 (FOXA2) co-expressing neurons. We further optimized the induction protocol by applying the small molecule inhibitor, CHIR99021 (CHIR).This helped facilitate the generation of midbrain dopaminergic neurons, and we obtained 31-74% midbrain dopaminergic neurons based on tyrosine hydroxylase and FOXA2 staining. Thus, we have established three induction protocols for dopaminergic neurons. Based on tyrosine hydroxylase and FOXA2 immunostaining analysis, the CHIR, SHH, and FGF8 combined protocol produces a much higher proportion of midbrain dopaminergic neurons, which could be an ideal resource for tackling midbrain-related diseases.

Citing Articles

Transcription Factor-Mediated Generation of Dopaminergic Neurons from Human iPSCs-A Comparison of Methods.

McDonald K, Lyons N, Gray L, Xu J, Schoderboeck L, Hughes S Cells. 2024; 13(12.

PMID: 38920646 PMC: 11201854. DOI: 10.3390/cells13121016.

Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders.

Cohen J, Mathew A, Dourvetakis K, Sanchez-Guerrero E, Pangeni R, Gurusamy N Cells. 2024; 13(6.

PMID: 38534355 PMC: 10969521. DOI: 10.3390/cells13060511.

References

Castelo-Branco G, Wagner J, Rodriguez F, Kele J, Sousa K, Rawal N . Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci U S A. 2003; 100(22):12747-52. PMC: 240689. DOI: 10.1073/pnas.1534900100. View

Ye W, Shimamura K, Rubenstein J, Hynes M, Rosenthal A . FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell. 1998; 93(5):755-66. DOI: 10.1016/s0092-8674(00)81437-3. View

Schwartz C, Tavakoli T, Jamias C, Park S, Maudsley S, Martin B . Stromal factors SDF1α, sFRP1, and VEGFD induce dopaminergic neuron differentiation of human pluripotent stem cells. J Neurosci Res. 2012; 90(7):1367-81. PMC: 3350575. DOI: 10.1002/jnr.23064. View

Zayed M, Sultan S, Alsaab H, Yousof S, Alrefaei G, Alsubhi N . Stem-Cell-Based Therapy: The Celestial Weapon against Neurological Disorders. Cells. 2022; 11(21). PMC: 9655836. DOI: 10.3390/cells11213476. View

Karvas R, David L, Theunissen T . Accessing the human trophoblast stem cell state from pluripotent and somatic cells. Cell Mol Life Sci. 2022; 79(12):604. PMC: 9702929. DOI: 10.1007/s00018-022-04549-y. View

Katsuki H, Kurimoto E, Takemori S, Kurauchi Y, Hisatsune A, Isohama Y . Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-mediated signaling. J Neurochem. 2009; 110(2):707-18. DOI: 10.1111/j.1471-4159.2009.06171.x. View

Kriks S, Shim J, Piao J, Ganat Y, Wakeman D, Xie Z . Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011; 480(7378):547-51. PMC: 3245796. DOI: 10.1038/nature10648. View

Tian L, Al-Nusaif M, Chen X, Li S, Le W . Roles of Transcription Factors in the Development and Reprogramming of the Dopaminergic Neurons. Int J Mol Sci. 2022; 23(2). PMC: 8775916. DOI: 10.3390/ijms23020845. View

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

10.

Kouwenhoven W, Von Oerthel L, Smidt M . Pitx3 and En1 determine the size and molecular programming of the dopaminergic neuronal pool. PLoS One. 2017; 12(8):e0182421. PMC: 5553812. DOI: 10.1371/journal.pone.0182421. View

11.

Ono Y, Nakatani T, Sakamoto Y, Mizuhara E, Minaki Y, Kumai M . Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development. 2007; 134(17):3213-25. DOI: 10.1242/dev.02879. View

12.

Wang M, Jin P, Bumcrot D, Marigo V, McMahon A, Wang E . Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein. Nat Med. 1995; 1(11):1184-8. DOI: 10.1038/nm1195-1184. View

13.

Chambers S, Fasano C, Papapetrou E, Tomishima M, Sadelain M, Studer L . Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009; 27(3):275-80. PMC: 2756723. DOI: 10.1038/nbt.1529. View

14.

Kim T, Piao J, Koo S, Kriks S, Chung S, Betel D . Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. Cell Stem Cell. 2021; 28(2):343-355.e5. PMC: 8006469. DOI: 10.1016/j.stem.2021.01.005. View

15.

Yeap Y, Teddy T, Lee M, Goh M, Lim K . From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson's Disease Modeling and Regenerative Therapy. Int J Mol Sci. 2023; 24(3). PMC: 9917335. DOI: 10.3390/ijms24032523. View

16.

Yang F, Feng L, Zheng F, Johnson S, Du J, Shen L . GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. Nat Neurosci. 2001; 4(11):1071-8. DOI: 10.1038/nn734. View

17.

Alekseenko Z, Dias J, Adler A, Kozhevnikova M, van Lunteren J, Nolbrant S . Robust derivation of transplantable dopamine neurons from human pluripotent stem cells by timed retinoic acid delivery. Nat Commun. 2022; 13(1):3046. PMC: 9160024. DOI: 10.1038/s41467-022-30777-8. View

18.

Tanudjojo B, Shaikh S, Fenyi A, Bousset L, Agarwal D, Marsh J . Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons. Nat Commun. 2021; 12(1):3817. PMC: 8217249. DOI: 10.1038/s41467-021-23682-z. View

19.

Guyon A, Skrzydelsi D, Rovere C, Rostene W, Melik Parsadaniantz S, Nahon J . Stromal cell-derived factor-1alpha modulation of the excitability of rat substantia nigra dopaminergic neurones: presynaptic mechanisms. J Neurochem. 2006; 96(6):1540-50. DOI: 10.1111/j.1471-4159.2006.03659.x. View

20.

Kirkeby A, Grealish S, Wolf D, Nelander J, Wood J, Lundblad M . Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 2012; 1(6):703-14. DOI: 10.1016/j.celrep.2012.04.009. View